# A Study to Collect Information on the Characteristics of Elderly Belgian Patients With NVAF That Are Treated With a NOAC for This Indication With a Special Focus on Their Fear of Bleeding While Using a NOAC vs the Clinical Benefit of a NOAC of Thrombosis/Stroke Prevention.

> **NCT04722679** · — · COMPLETED · sponsor: **Bayer** · enrollment: 103 (actual)

## Conditions studied

- Non-Valvular Atrial Fibrillation

## Interventions

- **DRUG:** Non-VKA Oral Anticoagulants (NOAC)

## Key facts

- **NCT ID:** NCT04722679
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-11
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-01-03
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2022-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04722679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04722679, "A Study to Collect Information on the Characteristics of Elderly Belgian Patients With NVAF That Are Treated With a NOAC for This Indication With a Special Focus on Their Fear of Bleeding While Using a NOAC vs the Clinical Benefit of a NOAC of Thrombosis/Stroke Prevention.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04722679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*